CARA Projected Dividend Yield
Cara Therapeutics Inc ( NASDAQ : CARA )Cara Therapeutics is an early commercial-stage biopharmaceutical company focusing on a new treatment paradigm to improve the lives of patients suffering from pruritus. Co.'s KORSUVA injection is an FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease, in adults undergoing hemodialysis. Co. is developing an Oral KORSUVA (difelikefalin) formulation for the treatment of pruritus in patients with atopic dermatitis, and non-dialysis-dependent chronic kidney disease. Phase 2 trials of Oral KORSUVA (difelikefalin) are ongoing in primary biliary cholangitis, and in notalgia paresthetica patients with moderate-to-severe pruritus. 20 YEAR PERFORMANCE RESULTS |
CARA Dividend History Detail CARA Dividend News CARA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |